Mylan debuts first generic of Xibrom ophthalmic solution and Risperidal, as well as Amrix which Watson also debuts
The last few days have seen US generic drug major Mylan (Nasdaq: MYL) introduce copy versions of several significant drugs in the USA, through its subsidiary Mylan Pharmaceuticals.
Yesterday Mylan launched bromfenac ophthalmic Solution, 0.09% (twice daily administration), based on a development and supply agreement with Coastal Pharmaceuticals. This product is the first generic version of ISTA's Xibrom Ophthalmic Solution, 0.09%, a treatment for postoperative inflammation in patients who have undergone cataract extraction. Bromfenac ophthalmic solution had US sales of around $116 million for the 12 months ending March 31, 2011, according to IMS Health.
180 days of marketing exclusivity for Amrix
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze